Nivolumab in the Real World in Patients With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
Latest Information Update: 17 May 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms VOLUME-PRO
- Sponsors Bristol-Myers Squibb
- 02 May 2022 Status changed from active, no longer recruiting to completed.
- 08 Oct 2021 New trial record